StockData
BioXcel Therapeutics, Inc. logo

BioXcel Therapeutics, Inc. (BTAIQ) stock

BTAIQOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 3/30
$0.03−0.00 (-13.49%)

Close on Oct 19, 2026Market cap $757.50KP/E –Yield –

BioXcel Therapeutics cash

Cash and short-term investments held at the end of each period.

BioXcel Therapeutics's cash was $12.84M at Jun 30, 2026. For fiscal 2025 it was $28.42M, down 4.8% from the year before. The highest annual figure on record is $232.97M in fiscal 2021.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$28.42M-4.8%
FY2024Dec 31, 2024$29.85M-54.2%
FY2023Dec 31, 2023$65.22M-66.3%
FY2022Dec 31, 2022$193.73M-16.8%
FY2021Dec 31, 2021$232.97M+9.3%
FY2020Dec 31, 2020$213.12M+557.2%
FY2019Dec 31, 2019$32.43M-23.8%
FY2018Dec 31, 2018$42.57M+4698.8%
FY2017Dec 31, 2017$887.00K–
FY2016Dec 31, 2016$0–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$12.84M-26.3%
Q1 FY2026Mar 31, 2026$17.18M-44.6%
Q4 FY2025Dec 31, 2025$28.42M-4.8%
Q3 FY2025Sep 30, 2025$36.18M-10.4%
Q2 FY2025Jun 30, 2025$17.44M-69.0%
Q1 FY2025Mar 31, 2025$31.01M-58.2%
Q4 FY2024Dec 31, 2024$29.85M-54.2%
Q3 FY2024Sep 30, 2024$40.39M-55.1%
Q2 FY2024Jun 30, 2024$56.27M-55.9%
Q1 FY2024Mar 31, 2024$74.14M-55.2%
Q4 FY2023Dec 31, 2023$65.22M-66.3%
Q3 FY2023Sep 30, 2023$89.96M-61.3%
Q2 FY2023Jun 30, 2023$127.55M-45.4%
Q1 FY2023Mar 31, 2023$165.52M-17.4%
Q4 FY2022Dec 31, 2022$193.73M-16.8%
Q3 FY2022Sep 30, 2022$232.31M-8.1%
Q2 FY2022Jun 30, 2022$233.45M-14.5%
Q1 FY2022Mar 31, 2022$200.44M+3.3%
Q4 FY2021Dec 31, 2021$232.97M+9.3%
Q3 FY2021Sep 30, 2021$252.91M+8.3%
Q2 FY2021Jun 30, 2021$273.06M+316.9%
Q1 FY2021Mar 31, 2021$194.02M+142.3%
Q4 FY2020Dec 31, 2020$213.12M+557.2%
Q3 FY2020Sep 30, 2020$233.43M+479.9%
Q2 FY2020Jun 30, 2020$65.50M+118.6%
Q1 FY2020Mar 31, 2020$80.08M+120.6%
Q4 FY2019Dec 31, 2019$32.43M-23.8%
Q3 FY2019Sep 30, 2019$40.25M-14.6%
Q2 FY2019Jun 30, 2019$29.97M-40.5%
Q1 FY2019Mar 31, 2019$36.30M-34.6%
Q4 FY2018Dec 31, 2018$42.57M+4698.8%
Q3 FY2018Sep 30, 2018$47.12M+6149.6%
Q2 FY2018Jun 30, 2018$50.35M+17566.3%
Q1 FY2018Mar 31, 2018$55.47M–
Q4 FY2017Dec 31, 2017$887.00K–
Q3 FY2017Sep 30, 2017$754.00K–
Q2 FY2017Jun 30, 2017$285.00K–
Q1 FY2017Mar 31, 2017$0–
Q4 FY2016Dec 31, 2016$0–

More BioXcel Therapeutics figures

See a number that looks wrong?